India Biotech Briefing - Dr. Brian W. Tempest

jamaicanabsorbingBiotechnology

Dec 5, 2012 (4 years and 6 months ago)

235 views

Hale & Tempest

India Biotech Briefing







Dr. Brian W Tempest


www.briantempest.com



IBIZ Conference, NHS Expo


Excel London UK 9 March 2011



Hale & Tempest

Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on
their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia
and India where he has lived for the last decade.

Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director
and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until
2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a
result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo
where he was responsible for businesses in Japan, China, Korea, and Taiwan.

Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in
North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions
at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE


India, Religare
-
India and UNCTAD
-

Switzerland. In addition he is a member of the SCRIP Global
awards panel. Brian speaks at global conferences on the Challenge from India and China and more
information on these presentations can be found on his website www.briantempest.com.

Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal
Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now
Chairman of Hale & Tempest Co Ltd.

Hale & Tempest


President, CEO, Non Exec Indian Pharma
Company
-

Ranbaxy 1995
-
2008


One of the few westerners to have a lead a
Sensex 50 blue chip Indian MNC


Resided in India 2000
-
2010, bought & sold
homes in Delhi, today an Indian pensioner and
Indian tax payer


Non Exec Chairman, Indian Investment Bank,
Religare Capital Markets


Non Exec Director, Indian Diagnostic Company,
SRL


Non Exec Director, Indian Healthcare Company


Fortis Global Healthcare

India Briefing

Hale & Tempest

The Indian Education Advantage

Engineers/Science graduates pa


India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

Hale & Tempest



Indian Businesses are Global

Pharma Exports by Country



Hale & Tempest

Indian Pharma Sales by Geography
Source Ranbaxy 2006

Europe & CIS
25%
API
8%
Americas
33%
Asia
27%
Africa
7%
$ 1.34b

Hale & Tempest



India Pharma Market Projections
Source IPA



Hale & Tempest

FDA Approved Manufacturing Sites

source FDA



Hale & Tempest



USA DMFs ex India



Hale & Tempest



USA DMFs ex China
Source FDA



Hale & Tempest

India represents 50% of USA ANDAs



Hale & Tempest

Top Generics Companies
Source Generics Bulletin June 2009



Hale & Tempest

Middle Size Generics Companies
Source Generics Bulletin June 2009



Hale & Tempest

WHO Pre Qualified Products



Hale & Tempest

Discovery Services in India

Hale & Tempest




Early discovery leads from USA, Europe or Singapore




Molecular optimisation from India



Toxicology from China, Central Europe, Singapore




Electronic Data Capture India



API Manufacture India



Drug Formulation Manufacture India, USA



Phase 1 Clinical Trials Europe



Phase 2,3 heavy use of India



Corporate back office India






India and Global Drug Development

Hale & Tempest



Biosimilar Distributors
Source IMS



Hale & Tempest



India R&D Investment



Hale & Tempest

Thank You

brian.tempest@clara.co.uk

www.briantempest.com


Hale & Tempest

India UKIBC Briefing







Dr. Brian W Tempest


www.briantempest.com



UK India Business Council


Manchester 10 March 2011